PASADENA, CA, May 30, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) today announced that a recently published article in the journal Cancer Research showed that PP2A, the pharmacologic target of LIXTE’s lead clinical compound, LB-100, when inactivated in pre-clinical models of glioma, activates…Read More
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnologys Lead Clinical Compound LB100 Increases Effectiveness of Cancer Immunotherapy
